• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

VLX600

CAS No. 327031-55-0

VLX600 ( —— )

产品货号. M21963 CAS No. 327031-55-0

VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥389 有现货
10MG ¥624 有现货
25MG ¥1280 有现货
50MG ¥2130 有现货
100MG ¥3645 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    VLX600
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.
  • 产品描述
    VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.?It acts by reducing mitochondrial oxidative phosphorylation in tumor cells.VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues.?The anticancer activity is associated with reduced mitochondrial respiration, leading to bioenergetic catastrophe and tumour cell death.?VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation.?Importantly, VLX600 displays tumour growth inhibition in vivo.?
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    oxidative phosphorylation (OXPHOS)
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    327031-55-0
  • 分子量
    317.35
  • 分子式
    C17H15N7
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO:8 mg/ml(25.21 mM)
  • SMILES
    C\C(=N/Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Xiaonan Zhang , M?rten Frykn?s , Emma Hernlund,et al. Induction of Mitochondrial Dysfunction as a Strategy for Targeting Tumour Cells in Metabolically Compromised Microenvironments[J].Nat Commun. 2014;5:3295.2. Karlsson H, et al. A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget. 2019 Sep 3;10(51):5372-5382.3. Arun Kanakkanthara , Kiran Kurmi , Thomas L Ekstrom, et al.BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents[1].Cancer Res. 2019 Dec 1;79(23):5920-5929.
产品手册
关联产品